Literature DB >> 3964556

Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.

G J Kontoghiorghes, A V Hoffbrand.   

Abstract

Increased daily iron excretion from iron overloaded, 59Fe lactoferrin labelled rabbits was observed following the intragastric administration of 1,2-dimethyl-3-hydroxy pyrid-4-one (L1) or 1-ethyl-2-methyl-3-hydroxy pyrid-4-one (L1-NEt) at doses of 200 mg/kg. 59Fe excretion induced by these drugs was predominantly faecal and was comparable to that caused by similar doses of subcutaneous or intramuscular desferrioxamine. The effectiveness of the two alpha-ketohydroxy pyridine chelators was confirmed by repeated administration, intragastrically or by subcutaneous or intramuscular injection, to the same or other rabbits. Examination of the urine during the administration of the chelators revealed their high specificity for iron but not for copper, zinc, calcium or magnesium.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3964556     DOI: 10.1111/j.1365-2141.1986.tb04082.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  [Effect of Maillard products and lysinoalanine on the bioavailability of iron, copper and zinc].

Authors:  G Rehner; T Walter
Journal:  Z Ernahrungswiss       Date:  1991-02

2.  Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators.

Authors:  G J Kontoghiorghes; S Chambers; A V Hoffbrand
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

3.  Oral iron chelating drugs: coming but not yet ready for clinical use.

Authors:  C Hershko
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-16

4.  Iron chelating drugs.

Authors:  G J Kontoghiorghes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-11

5.  Investigation of the anti-inflammatory properties of hydroxypyridinones.

Authors:  S D Hewitt; R C Hider; P Sarpong; C J Morris; D R Blake
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

6.  Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.

Authors:  G J Kontoghiorghes; L Sheppard; A V Hoffbrand; J Charalambous; J Tikerpae; M J Pippard
Journal:  J Clin Pathol       Date:  1987-04       Impact factor: 3.411

Review 7.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 8.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

Authors:  G J Kontoghiorghes; M A Aldouri; A V Hoffbrand; J Barr; B Wonke; T Kourouclaris; L Sheppard
Journal:  Br Med J (Clin Res Ed)       Date:  1987-12-12

10.  Synthesis, analysis and cytotoxic evaluation of some hydroxypyridinone derivatives on HeLa and K562 cell lines.

Authors:  L Saghaie; H Sadeghi-Aliabadi; M Ashaehshoar
Journal:  Res Pharm Sci       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.